실적분석 2026년 8월 3일

Jazz Pharmaceuticals ($JAZZ) 2026 Q2 Earnings Analysis — Revenue Surprise, Guidance Raised, Adjusted EPS Misses Estimates

Earnings Scorecard

Revenue: $1.208 billion (+16% YoY, estimate $1.114 billion) ✅ Beat

EPS: Adjusted $5.71 (estimate $6.18) ❌ Miss

Guidance: Raised — 2026 full-year revenue $4.60–$4.75 billion (prior $4.25–$4.50 billion)

Stock Reaction: After-hours +2.15% ($257) — as of 08-04 05:59 KST

Positives

Record quarterly revenue: Total revenue of $1.208 billion, up 16% YoY, exceeding the consensus

Core product growth: Xywav (+13%), Epidiolex (+16%), Zepzelca (+42%)

Full-year guidance raised: 2026 revenue outlook lifted to $4.60–$4.75 billion

Net product sales of sleep-disorder therapy Xywav reached $471 million in 2026 Q2, up 13% YoY, with approximately 525 new patients added, bringing active patients to around 17,125 at quarter-end. Epidiolex for epilepsy posted $292 million (+16%), and oncology drug Zepzelca surged 42% to $106 million. Modeyso, added following its August 2025 approval, contributed an additional $48.2 million.

The company generated $824 million in operating cash flow during the first half and held cash, cash equivalents, and investments of approximately $2.2 billion as of the end of June. The supplemental Biologics License Application for zanidatamab (Ziihera) in first-line HER2-positive gastroesophageal adenocarcinoma has been accepted for priority review with a Prescription Drug User Fee Act (PDUFA) target date of August 25, 2026, drawing market attention as the next leg of the commercial expansion.

Negatives

Adjusted EPS shortfall: Adjusted EPS of $5.71 missed the $6.18 consensus

One-time R&D charge: In-process R&D expenses of $77 million related to acquisitions and collaborations ($0.94 per share impact)

Product and label risks: Zepzelca label removal planned for a second indication; high-sodium oxybate royalty decline

Adjusted (non-GAAP) EPS of $5.71 fell short of the $6.18 analyst estimate. The company disclosed that in-process R&D (IPR&D) charges of $77 million — related to the Axcelera collaboration upfront and the buyout of remaining Werewolf rights — amounting to $65.4 million after tax, or $0.94 per share, were reflected in both GAAP and adjusted results. While largely one-time in nature, the burden was fully exposed when measured against the consensus.

Zepzelca grew on first-line maintenance demand, but based on the Lagoon trial results and U.S. Food and Drug Administration (FDA) discussions, the company plans to file a supplement in 2026 Q3 to remove the second-line metastatic small-cell lung cancer indication from the label. The first-line maintenance indication remains. High-sodium oxybate authorized-generic royalties declined from $54.1 million a year earlier to $42.2 million, and sales of certain oncology products including Venclexta also fell, creating uneven performance within the portfolio.

What the Company Said

CEO Renee Gala emphasized that the Q2 results reflect strong execution and momentum across the business, delivering 16% YoY revenue growth and a meaningful increase to full-year revenue guidance. She positioned the launch of Ziihera in first-line gastroesophageal adenocarcinoma, the progression of zanidatamab and Epidiolex clinical programs, and pipeline expansion through acquisitions and internal R&D as the long-term growth pillars.

The tone leaned toward commercial confidence and placed weight on second-half approval and launch catalysts. The company raised only revenue guidance explicitly, omitting adjusted EPS and other profit-line guidance from the press release tables, leaving the market to first read through revenue momentum and the late-August zanidatamab approval timeline.

Market Reaction and Key Watchpoints

The revenue surprise and raised full-year revenue guidance appear to have offset the adjusted EPS miss. The one-time charges such as in-process R&D weighed on earnings, and the proximity of the August 25 zanidatamab approval target date also reads as a backdrop to the modest after-hours gain. For the stock price, please refer to the scorecard above.

Ziihera (zanidatamab) first-line gastroesophageal adenocarcinoma supplemental approval result and launch readiness around August 25, 2026

Second interim overall survival analysis of the Herizon-ZiHe-01 combination therapy, scheduled for 2026 Q3

Impact of the planned Zepzelca second-line label removal on growth momentum in the first-line maintenance setting